Diagnostic Assay Development (c-Abl/RIPK2)
Parkinson's Disease, Alzheimer's Disease, Neurodegenerative Diseases
Pre-clinicalActive
Key Facts
Indication
Parkinson's Disease, Alzheimer's Disease, Neurodegenerative Diseases
Phase
Pre-clinical
Status
Active
Company
About ValtedSeq
ValtedSeq is a private, pre-clinical biotech company pioneering a data-driven approach to neurodegenerative diseases. Founded by renowned Johns Hopkins scientists Dr. Ted Dawson and Dr. Valina Dawson, the company's core asset is its HiF-Seq™ platform, which enables high-efficiency single-cell sequencing from frozen brain tissue to create an unprecedented data repository. This data fuels the discovery of novel therapeutic targets and the development of ultra-sensitive diagnostic assays, particularly targeting pathways like PAR and c-Abl. As a subsidiary of D&D Pharmatech/Neuraly, ValtedSeq is positioned to translate its foundational discoveries into clinical programs.
View full company profile